XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($) $ in Thousands		1 Months Ended			9 Months Ended	12 Months Ended
	Oct. 06, 2021	Sep. 30, 2022	Aug. 31, 2022	Jan. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Agreements
Long-term royalty and commercial payment receivables		$ 66,049			$ 66,049	$ 69,075
Contingent consideration under RPAs and CPPAs		75			75	8,075
Impairment of long-term royalty receivable					0	0
Affitech \| Commercial Payment Purchase Agreement
Agreements
Upfront payment	$ 6,000
Maximum additional payments upon achievement of regulatory and sales milestones	20,000
Long-term royalty and commercial payment receivables	14,000
Maximum payable on regulatory milestone	8,000
Maximum payable on sales milestone	$ 12,000
Milestone payment		$ 3,000		$ 5,000
Cash receipts for achievement of contractual milestones			$ 500
Impairment of long-term royalty receivable					0	0
Affitech \| Commercial Payment Purchase Agreement \| Faricimab
Agreements
Payments eligible to receive (as a percent)	0.50%
Commercial payment receivable term	10 years
Affitech \| Commercial Payment Purchase Agreement \| VABYSMO
Agreements
Payments eligible to receive (as a percent)		0.50%
Commercial payment receivable term		10 years
Affitech \| Commercial Payment Purchase Agreement \| Regulatory milestones
Agreements
Contingent consideration under RPAs and CPPAs	$ 8,000	$ 0			0	$ 8,000
Affitech \| Commercial Payment Purchase Agreement \| Sales milestones
Agreements
Contingent consideration under RPAs and CPPAs		$ 0			$ 0